Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic adenovirus-specific cytotoxic T lymphocytes
- Development stage
- Phase 1
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic adenovirus-specific cytotoxic T lymphocytes (CTLs) is an 'off-the-shelf' adoptive cell therapy developed by the M.D. Anderson Cancer Center. This biologic therapy consists of donor-derived T lymphocytes that have been expanded ex vivo and sensitized to target adenovirus antigens. The therapy is designed for immunocompromised patients, such as those who have undergone hematopoietic stem cell transplantation, who develop life-threatening adenovirus viremia or disease. By using banked, HLA-matched CTLs from third-party donors, the treatment provides immediate antiviral immunity without the delay of custom manufacturing or the high risk of graft-versus-host disease typically associated with unselected donor lymphocyte infusions.
- Other names
- off-the-shelf adenovirus-specific T cellsthird-party adenovirus-specific T cellsdonor-derived adenovirus-specific CTLsAdV-VSTAdV-CTL
02
Targets
Adenoviral penton-derived epitopesHexon (Adenovirus hexon protein)HAdV (Human adenovirus)
Beyond the preview
Go deeper on allogeneic adenovirus-specific cytotoxic T lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic adenovirus-specific cytotoxic T lymphocytes.